13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001799883
Total reported value
$287.9M
$287.9M
31 檔
39.2%
At the close of Q1 2025, 5AM Venture Management, LLC disclosed equity holdings valued at approximately $287.9M, spread across 31 reported holdings.
In Q1 2025, 5AM Venture Management, LLC displayed an active expansion posture, initiating 29 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TRDA | Entrada Therapeutics Inc | Stock-Other | 15.07% | -3.84% | — | |
| 2 | ELVN | Enliven Therapeutics Inc | Stock-Other | 9.84% | — | -18.85% | |
| 3 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 7.05% | — | — | |
| 4 | SKYE | Skye Bioscience Inc | Stock-Other | 5.96% | +0.68% | — | |
| 5 | PHVS | Pharvaris N.V. | Stock-Other | 4.74% | +3.32% | — | |
| 6 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 4.52% | -6.41% | EXIT | |
| 7 | CAMP | Camp4 Therapeutics CORP | Stock-Other | 4.43% | +1.72% | — | |
| 8 | BHVN | Biohaven Ltd. | Stock-Other | 4.35% | +2.08% | — | |
| 9 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 4.17% | — | — | |
| 10 | VRDN | Viridian Therapeutics Inc | Stock-Other | 3.76% | — | — | |
| 11 | TECX | Tectonic Therapeutic Inc | Stock-Other | 3.43% | +2.03% | -14.25% | |
| 12 | CLDX | Celldex Therapeutics Inc | Stock-Other | 3.41% | +2.05% | — | |
| 13 | TYRA | Tyra Biosciences Inc | Stock-Other | 3.30% | +0.48% | — | |
| 14 | ERAS | Erasca Inc | Stock-Other | 2.80% | -15.66% | EXIT | |
| 15 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 2.67% | +3.72% | — | |
| 16 | ANAB | Anaptysbio Inc | Stock-Other | 2.52% | — | — | |
| 17 | PRAX | Praxis Precision Medicines I | Stock-Other | 2.43% | — | — | |
| 18 | GHRS | GH Research PLC | Stock-Other | 2.39% | -2.24% | EXIT | |
| 19 | EYPT | Eyepoint Inc | Stock-Other | 2.15% | +1.46% | — | |
| 20 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 1.73% | — | — | |
| 21 | VOR | Vor Biopharma Inc. | Stock-Other | 1.73% | — | — | |
| 22 | SRZN | Surrozen Inc | Stock-Other | 1.37% | -0.69% | — | |
| 23 | TARA | Protara Therapeutic Inc | Stock-Other | 1.29% | -0.16% | — | |
| 24 | SCPH | Scpharmaceuticals Inc | Stock-Other | 1.19% | — | — | |
| 25 | ✓ | Rallybio CORP | Stock-Other | 0.90% | — | — | |
| 26 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 0.90% | — | — | |
| 27 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.51% | +1.12% | — | |
| 28 | ALEC | Alector Inc | Stock-Other | 0.46% | — | — | |
| 29 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.46% | — | — | |
| 30 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.29% | +4.09% | — | |
| 31 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.17% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SCPH | Scpharmaceuticals Inc | -4.7% | — | Trim |
| 2 | VOR | Vor Biopharma Inc. | -29.7% | — | Trim |
| 3 | ✓ | Akouos Inc | — | EXIT | Sold out |
| 4 | TRDA | Entrada Therapeutics Inc | — | NEW | New buy |
| 5 | IDYA | Ideaya Biosciences Inc | — | EXIT | Sold out |
| 6 | FIXXEUR | Homology Medicines Inc | — | EXIT | Sold out |
| 7 | ARVN | Arvinas Inc | — | EXIT | Sold out |
| 8 | ELVN | Enliven Therapeutics Inc | — | NEW | New buy |
| 9 | CRNX | Crinetics Pharmaceuticals In | — | EXIT | Sold out |
| 10 | CABA | Cabaletta Bio Inc | — | EXIT | Sold out |
| 11 | IMPL1USD | Ipi Legacy Liquidation Co | — | EXIT | Sold out |
| 12 | DNTH | Dianthus Therapeutics Inc | — | NEW | New buy |
| 13 | SKYE | Skye Bioscience Inc | — | NEW | New buy |
| 14 | PHVS | Pharvaris N.V. | — | NEW | New buy |
| 15 | 260 | Centessa Pharmaceuticals-adr | — | NEW | New buy |
| 16 | CAMP | Camp4 Therapeutics CORP | — | NEW | New buy |
| 17 | BHVN | Biohaven Ltd. | — | NEW | New buy |
| 18 | JANX | Janux Therapeutics Inc | — | EXIT | Sold out |
| 19 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
| 20 | VRDN | Viridian Therapeutics Inc | — | NEW | New buy |
| 21 | TECX | Tectonic Therapeutic Inc | — | NEW | New buy |
| 22 | CLDX | Celldex Therapeutics Inc | — | NEW | New buy |
| 23 | TYRA | Tyra Biosciences Inc | — | NEW | New buy |
| 24 | ERAS | Erasca Inc | — | NEW | New buy |
| 25 | ARTV | Artiva Biotherapeutics Inc | — | NEW | New buy |
| 26 | ANAB | Anaptysbio Inc | — | NEW | New buy |
| 27 | PRAX | Praxis Precision Medicines I | — | NEW | New buy |
| 28 | GHRS | GH Research PLC | — | NEW | New buy |
| 29 | EYPT | Eyepoint Inc | — | NEW | New buy |
| 30 | VKTX | Viking Therapeutics Inc | — | NEW | New buy |
| 31 | ✓ | Cidara Therapeutics Inc Com New | — | EXIT | Sold out |
| 32 | ✓ | 5 01 Acquisition CORP | — | EXIT | Sold out |
| 33 | SRZN | Surrozen Inc | — | NEW | New buy |
| 34 | TARA | Protara Therapeutic Inc | — | NEW | New buy |
| 35 | ✓ | Rallybio CORP | — | NEW | New buy |
| 36 | AVU0 | Adverum Biotechnologies Inc | — | NEW | New buy |
| 37 | SLN | Silence Therapeutics Plc-adr | — | NEW | New buy |
| 38 | ALEC | Alector Inc | — | NEW | New buy |
| 39 | CDTX | Cidara Therapeutics Inc | — | NEW | New buy |
| 40 | ZNTL | Zentalis Pharmaceuticals Inc | — | NEW | New buy |
| 41 | ✓ | Mersana Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, 5AM Venture Management, LLC reported a total U.S. public equity portfolio value of $287.9M across 31 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TRDA, ELVN, DNTH) accounted for 39.2% of total reported equity market value during Q1 2025.
Top New Position Initiated
TRDA
市值: $39.9M
Top Position Liquidated / Trimmed
AKOUOS INC
前期市值: $51.9M
During Q1 2025, 5AM Venture Management, LLC's top holdings by market value included TRDA (15.1%)、ELVN (9.8%)、DNTH (7.0%). The largest single position, TRDA, represented 15.1% of total portfolio value.
In Q1 2025, 5AM Venture Management, LLC made 41 total portfolio adjustments, initiating 29 new buys, adding to 0 positions, trimming 2 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.